Omeros announces extension of fda review period for narsoplimab in hsct-tma

Seattle--(business wire)--omeros corporation (nasdaq: omer), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders, today reported that the u.s. food and drug administration (fda) will require additional time to review the biologics
OMER Ratings Summary
OMER Quant Ranking